A recent study compared two dosages of ifinatamab deruxtecan among patients with extensive-stage small cell lung cancer.

Ifinatamab deruxtecan has demonstrated antitumor activity as second-line or later therapy in patients with ES-SCLC.

Daiichi Sankyo and MSD (Merck & Co) have reported that the Phase III HERTHENA-Lung02 clinical trial of patritumab deruxtecan, ...

Results from an interim analysis of the dose-optimization part of the ongoing IDeate-Lung01 phase 2 trial showed ifinatamab deruxtecan (I-DXd) continu ...

Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC ...

The antibody–drug conjugate ifinatamab deruxtecan (I-DXd) showed clinically meaningful responses in pretreated patients with extensive-stage small cell lung cancer (ES-SCLC), according to an interim ...

Ifinatamab deruxtecan, a novel antibody-drug conjugate, returned promising response rates at both dose levels evaluated among ...

MSD and Daiichi Sankyo started enrolling patients into the phase 3 Ideate-Lung02 study in the summer.

ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.

Merck & Co., Inc. (MRK) and Daiichi Sankyo (DSKYF.PK) announced that an interim analysis of the dose-optimization phase of the ...

Patients with pretreated extensive small cell lung cancer could benefit from the antibody-drug conjugate ifinatamab ...